^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Bio-Techne

i
Other names: Lunaphore | ProteinSimple | Cell Biosciences | Bio-Techne Corporation | Techne Corporation | Bio-Techne | Exosome Diagnostics, Inc. | Exosome Diagnostics | R&D Systems, Inc. | Novus Biologicals | Novus Biologicals LLC | Novus Biologicals, LLC | Tocris Bioscience | Tocris | Asuragen | Asuragen, Inc. | Asuragen Inc. | Exosome Diagnostics, Inc | Exosome Diagnostics Inc. | Exosome Diagnostics Inc | Exosome Diagnostics GmbH | R&D Systems Inc. | R&D Systems Inc | R&D Systems, Inc | R&D Systems | Asuragen, Inc | Asuragen Inc | Bio-Techne Corp. | Bio-Techne Corp
Related tests:
Evidence

News

8d
Bio-Techne surpasses 10,000 peer-reviewed publications citing RNAscope technology (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's spatial biology division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology."
Clinical data
|
RNAscope™ ISH Probe High Risk HPV
15d
BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE (PRNewswire)
"Bio-Techne Corporation...announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, California. Bio-Techne will showcase its solutions at booth #541, featuring our market-leading portfolio of high-grade life science reagents, immunoassays, automated proteomic analytical instruments, and multiomics solutions that are enabling new drug discovery research, accelerating immune cell therapy, and supporting the development of better diagnostic tools. We will also be debuting our Journey into the Tumor Microenvironment video experience in our booth this year."
Clinical data • Clinical
27d
BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA (PRNewswire)
"Bio-Techne Corporation...has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR."
European regulatory
|
Quantidex qPCR BCR-ABL IS Kit
3ms
Bio-Techne's Advanced Cell Diagnostics (ACD) sets new standard in spatial biology with protease-free RNAscope multiomics (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow. Optimized for same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with both manual and automated assays. ACD's novel protease-free RNAscope workflow is incorporated in Bio-Techne's recently announced best-in-class multiomics application on Lunaphore's COMET platform."
Clinical
4ms
Lunaphore and SIB awarded Innosuisse funding to develop innovative AI-based assay development tools (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that Lunaphore, a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics, have been awarded Innosuisse funding for an innovation project. The collaboration aims to develop novel AI-based assay development tools for spatial biology on Lunaphore's COMET™ to further accelerate the adoption of multiplex sequential immunofluorescence (seqIF™) technology in research...Spatial biology utilizes detailed tissue analysis and intracellular interactions to enable profound insights in cancer biology, immuno-oncology, and other research fields."
Financing
6ms
Asuragen to present novel clinical testing data at AMP 2023 conference (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to...cancer monitoring, resolving conventionally inaccessible, disease-causing genes, and more at the upcoming meeting of the Association for Molecular Pathology (AMP), to be held November 14-18 in Salt Lake City, Utah."
Clinical data
6ms
LEADING RESEARCH INSTITUTES TO PRESENT NEW DATA USING LUNAPHORE’S COMET TECHNOLOGY AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 38th ANNUAL MEETING (PRNewswire)
"Bio-Techne Corporation...announced that Lunaphore, a Bio-Techne brand, will have its technologies featured in several presentations by prominent research centers at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place in San Diego, November 1-5, 2023. The recent studies will demonstrate the unmatched spatial biology capabilities of the company's universal, end-to-end COMET product suite, addressing complex biological questions from various research areas. COMET is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies, making panel design much more flexible and faster than any other hyperplex solution."
Clinical data
8ms
Sylvester Comprehensive Cancer Center wins $2.5M NCI grant to develop prostate cancer test (Genomeweb)
"Researchers at the University of Miami's Sylvester Comprehensive Cancer Center on Tuesday said they have been awarded a $2.5 million grant from the National Cancer Institute to develop an exosome-based prostate cancer test...The researchers will collaborate with Bio-Techne's Exosome Diagnostics to develop a more prostate cancer-specific platform based on the company's biomarker, the cancer center said in a statement."
Licensing / partnership • Grant
8ms
Bio-Techne ends collaboration program with Akoya to automate RNAscope on the Phenocycler Fusion (Bio-Techne Press Release)
"Bio-Techne...announced that the company will end their collaboration with Akoya Biosciences to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System...Bio-Techne will continue to support its customers utilizing RNAscope assays in conjunction with Opal™ reagents and PhenoImager™ HT systems purchased from Akoya."
Licensing / partnership
|
RNAscope™ ISH Probe High Risk HPV
9ms
Bio-Techne completes Lunaphore acquisition (Bio-Techne Press Release)
"Bio-Techne Corporation...announced it has completed the acquisition of Lunaphore Technologies SA...Bio-Techne and Lunaphore are combining forces to accelerate their spatial biology leadership position in translational and clinical research markets...Lunaphore's instrument portfolio includes COMET™, an end-to-end spatial biology platform, with tissue staining, imaging and image preprocessing steps integrated into a fully automated, high-throughput instrument, that delivers true walk-away automation with unmatched scalability, reproducibility, and retention of tissue morphology."
M&A
10ms
Bio-Techne to acquire Lunaphore (Bio-Techne Press Release)
"Bio-Techne Corporation...announced it has reached an agreement to acquire Lunaphore, Inc. Bio-Techne anticipates the acquisition to close in the first quarter of its fiscal 2024...Lunaphore's spatial biology technology enables the identification of biomarker 'signatures' with clinical relevance, providing data necessary to support the development of diagnostic tools and streamline clinical trials, and ultimately improve patient outcomes."
M&A
11ms
Exosome Diagnostics releases interim results from clinical study of prostate cancer risk test (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that Exosome Diagnostics...has reported interim results from a previously published prospective, randomized study of more than 1,000 patients aimed at evaluating the clinical utility of the ExoDx™ Prostate Test over a 5-year follow-up period. This study adds to the body of published evidence on the ExoDx Prostate Test. The results came out in a peer-reviewed paper published today in Prostate Cancer and Prostatic Diseases."
Clinical data
|
ExoDx™ Prostate (IntelliScore) Test
11ms
Bio-Techne commercializes RNAscope spatial biology workflow for the Standard Biotools Hyperion Imaging System (Bio-Techne Press Release)
"Bio-Techne...announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of a RNAscope multiomic workflow for the Standard BioTools Hyperion™ Imaging System...The new RNAscope HiPlex12 Flex Kit enables visualization of highly multiplexed RNA biomarkers using the Hyperion XTi or earlier models of the Hyperion Imaging System."
Commercial
11ms
Bio-Techne announces launch of kappa and lambda RNAScope ISH Probes as analyte specific reagents (ASRS) for the detection of immunoglobulin kappa and lambda light chains mRNA (Bio-Techne Press Release)
"Bio-Techne...announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents (ASRs) for the detection of immunoglobulin kappa and lambda light chains mRNA in B-cells...RNAscope ISH Probes Kappa and Lambda are designed to detect immunoglobulin kappa and lambda light chains mRNA. RNAscope probes are visualized with the highly sensitive RNAscope ISH detection reagents, which are compatible with FFPE tissue."
Launch
|
RNAscope™ ISH Probe High Risk HPV
almost1year
Bio-Techne and Lunaphore establish strategic partnership to develop the first fully automated same-slide spatial multiomics solution (Bio-Techne Press Release)
"Bio-Techne...and Lunaphore...announced a strategic partnership to develop the first fully automated spatial multiomics workflow with same-slide hyperplex detection of protein and RNA biomarkers. Designed to provide ultimate flexibility in panel design, the solution will allow researchers to easily combine well-characterized antibodies with gold-standard RNAscope™ in situ hybridization probes to illuminate changes in cell phenotypes and functional states across a wide range of diseases."
Licensing / partnership
|
RNAscope™ ISH Probe High Risk HPV
1year
Bio-Techne to showcase innovative cancer research, cell therapy and manufacturing tools at AACR 2023 conference (Bio-Techne Press Release)
"Bio-Techne Corporation...announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida."
Clinical data
|
RNAscope™ ISH Probe High Risk HPV
1year
ExoDx Prostate Test granted expanded coverage by Medicare (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that a newly finalized local coverage determination (LCD) from National Government Services, Inc., a Medicare Administrative Contractor, includes coverage for the ExoDx™ Prostate Test from Exosome Diagnostics, a Bio-Techne brand. The updated policy now covers an annual ExoDx Prostate Test for men who already had a negative biopsy but are thought to be at high risk for prostate cancer and are considering a repeat biopsy. The coverage will go into effect March 1, 2023."
Medicare • Reimbursement
|
ExoDx™ Prostate (IntelliScore) Test
almost2years
Bio-Techne Announces Launch of the CE-IVD RNAscope ISH Probe High Risk HPV Assay for Head and Neck Cancer (Bio-Techne Press Release)
"Bio-Techne...announced the European launch of the CE-IVD marked RNAscope ISH Probe High Risk HPV, intended for use in patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC) to aid in the identification of high-risk human papillomavirus (HPV)."
Launch Europe
|
RNAscope™ ISH Probe High Risk HPV
almost2years
Nonagen Bioscience and Bio-Techne announce exclusive supply agreement for Nonagen’s Oncuria® bladder cancer test (Nonagen Bioscience Press Release)
"Nonagen Bioscience and Bio-Techne Corporation...announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience’s Oncuria® bladder cancer diagnostic panel using xMAP Luminex® technology...Nonagen Bioscience and Bio-Techne are targeting the last quarter of calendar 2022 to make Oncuria available as an LDT."
Licensing / partnership
|
Oncuria™
almost2years
Bio-Techne to present at annual American Urological Association Conference in New Orleans (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that Exosome Diagnostics...will have a major scientific presence at the annual American Urological Association Conference (AUA) taking place May 13-16 in New Orleans, LA. Exosome Diagnostics will have two poster presentations, including a podium presentation, six in-booth scientific presentations...Additional presentations include results of the ExoDx™ Prostate test clinical utility study as well as a 2.5 year follow-up and interim analysis of subjects who participated in the study and will conclude with the combined performance of the ExoDx Prostate test and MRI in the early detection of prostate cancer."
Clinical data
|
ExoDx™ Prostate (IntelliScore) Test
2years
Bio-Techne announces publication of new data demonstrating ExoDX Prostate test correlation with post-prostatectomy pathology outcomes (Bio-Techne Press Release)
"Bio-Techne Corporation...announced an important publication in World Journal of Urology, entitled Pre–diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post–prostatectomy pathology outcome...The significance of this study is that in men with an EPI score below the cut-point of 15.6, the ExoDx Prostate test could prevent low-risk men from proceeding to radical prostatectomy."
Clinical data
|
ExoDx™ Prostate (IntelliScore) Test